结直肠癌是发病和死亡率较高的肿瘤,大约8%~10%的晚期结肠直肠癌(Colorectal Cancer, CRC)患者出现BRAF改变,特别是V600E突变。并且BRAF突变(BRAF-mt)预后不良与多种因素相关,已被确定为治疗优化的一个重要目标。目前,治疗标准是一种涉及三联化疗和抗EGFR药物的积极策略,但新的治疗方法正在出现。通过查阅国内外相关文献对BRAF突变结直肠癌的预后及治疗研究进展进行综述。
Colorectal cancer is a tumor with high morbidity and mortality, and approximately 8%~10% of pa-tients with advanced colorectal cancer (CRC) have BRAF alterations, especially the V600E mutation. And BRAF mutation (BRAF-mt), with poor prognosis associated with multiple factors, has been identified as an important target for treatment optimization. Currently, the standard of care is an aggressive strategy involving triple chemotherapy and anti-EGFR drugs, but new treatments are emerging. The research progress of prognosis and treatment of BRAF-mutated colorectal cancer was reviewed by reviewing relevant domestic and foreign literatures.
结直肠癌,BRAF突变,预后,免疫治疗, Colorectal Cancer BRAF Mutation Prognosis Immunity Therapy摘要
Advances in Prognosis and Treatment of Colorectal Cancer with BRAF Mutation
Qi Chen1, Yuying Li2
1Qingha University, Xining Qinghai
2Affiliated Hospital of Qinghai University, Xining Qinghai
Received: Apr. 25th, 2022; accepted: May 19th, 2022; published: May 27th, 2022
ABSTRACT
Colorectal cancer is a tumor with high morbidity and mortality, and approximately 8%~10% of patients with advanced colorectal cancer (CRC) have BRAF alterations, especially the V600E mutation. And BRAF mutation (BRAF-mt), with poor prognosis associated with multiple factors, has been identified as an important target for treatment optimization. Currently, the standard of care is an aggressive strategy involving triple chemotherapy and anti-EGFR drugs, but new treatments are emerging. The research progress of prognosis and treatment of BRAF-mutated colorectal cancer was reviewed by reviewing relevant domestic and foreign literatures.
陈 琪,李瑜英. BRAF突变的结直肠癌预后及治疗研究进展Advances in Prognosis and Treatment of Colorectal Cancer with BRAF Mutation[J]. 临床医学进展, 2022, 12(05): 4565-4570. https://doi.org/10.12677/ACM.2022.125659
参考文献ReferencesSung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
<br>https://doi.org/10.3322/caac.21660Chen, W., Xia, C., Zheng, R., et al. (2019) Disparities by Province, Age, and Sex in Site-Specific Cancer Burden Attributable to 23 Potentially Modifiable Risk Factors in China: A Comparative Risk Assessment. The Lancet Global Health, 7, e257-e269. <br>https://doi.org/10.1016/S2214-109X(18)30488-1Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Sta-tistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. <br>https://doi.org/10.3322/caac.21338Grothey, A., Fakih, M. and Tabernero, J. (2021) Management of BRAF-Mutant Metastatic Colorectal Cancer: A Review of Treatment Options and Evidence-Based Guidelines. Annals of Oncology, 32, 959-967.
<br>https://doi.org/10.1016/j.annonc.2021.03.206Tabbo, F., Pisano, C., Mazieres, J., et al. (2022) How Far We Have Come Targeting BRAF-Mutant Non-Small Cell Lung Cancer (NSCLC). Cancer Treatment Reviews, 103, Article ID: 102335. <br>https://doi.org/10.1016/j.ctrv.2021.102335Dankner, M., Rose, A., Rajkumar, S., Siegel, P.M. and Watson, I. (2018) Classifying BRAF Alterations in Cancer: New Rational Therapeutic Strategies for Actionable Mu-tations. Oncogene, 37, 3183-3199.
<br>https://doi.org/10.1038/s41388-018-0171-xSun, J., Carr, M.J. and Khushalani, N.I. (2020) Principles of Tar-geted Therapy for Melanoma. Surgical Clinics of North America, 100, 175-188. <br>https://doi.org/10.1016/j.suc.2019.09.013Pickles, O.J., Drozd, A., Tee, L., Beggs, A.D. and Middleton, G.W. (2020) Paradox Breaker BRAF Inhibitors Have Comparable Potency and MAPK Pathway Reactivation to Encorafenib in BRAF Mutant Colorectal Cancer. Oncotarget, 11, 3188-3197. <br>https://doi.org/10.18632/oncotarget.27681Van Cutsem, E., Cervantes, A., Nordlinger, B. and Arnold, D. (2014) Metastatic Colorectal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 25, iii1-9.
<br>https://doi.org/10.1093/annonc/mdu260Bachet, J.B., Moreno-Lopez, N., Vigano, L., et al. (2019) BRAF Mutation Is Not Associated with an Increased Risk of Recurrence in Patients Undergoing Resection of Colorectal Liver Metastases. British Journal of Surgery, 106, 1237-1247.
<br>https://doi.org/10.1002/bjs.11180Tumeh, P.C., Hellmann, M.D., Hamid, O., et al. (2017) Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immu-nology Research, 5, 417-424.
<br>https://doi.org/10.1158/2326-6066.CIR-16-0325Bouviez, N., Lakkis, Z., Lubrano, J., et al. (2014) Liver Re-section for Colorectal Metastases: Results and Prognostic Factors with 10-Year Follow-Up. Langenbeck’s Archives of Surgery, 399, 1031-1038.
<br>https://doi.org/10.1007/s00423-014-1229-zPrimrose, J.N. (2010) Surgery for Colorectal Liver Metastases. British Journal of Cancer, 102, 1313-1318.
<br>https://doi.org/10.1038/sj.bjc.6605659Kopetz, S., Chang, G.J., Overman, M.J., et al. (2009) Improved Sur-vival in Metastatic Colorectal Cancer Is Associated with Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical Oncology, 27, 3677-3683.
<br>https://doi.org/10.1200/JCO.2008.20.5278Chen, K.H., Lin, Y.L., Liau, J.Y., et al. (2016) BRAF Mutation May Have Different Prognostic Implications in Early- and Late-Stage Colorectal Cancer. Medical Oncology, 33, 39. <br>https://doi.org/10.1007/s12032-016-0756-6Poulogiannis, G., Frayling, I.M. and Arends, M.J. (2010) DNA Mismatch Repair Deficiency in Sporadic Colorectal Cancer and Lynch Syndrome. Histopathology, 56, 167-179. <br>https://doi.org/10.1111/j.1365-2559.2009.03392.xChang, X.N., Shang, F.M., Jiang, H.Y., et al. (2021) Clinicopathological Features and Prognostic Value of KRAS/ NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China. Current Medical Science, 41, 118-126.
<br>https://doi.org/10.1007/s11596-021-2326-1Kopetz, S., Guthrie, K.A., Morris, V.K., et al. (2021) Randomized Trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology, 39, 285- 294. <br>https://doi.org/10.1200/JCO.20.01994Tabernero, J., Grothey, A., Van Cutsem, E., et al. (2021) Encorafenib plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 39, 273-284. <br>https://doi.org/10.1200/JCO.20.02088Weisenberger, D.J., Siegmund, K.D., Campan, M., et al. (2006) CpG Island Methylator Phenotype Underlies Sporadic Microsatellite Instability and Is Tightly Associated with BRAF Muta-tion in Colorectal Cancer. Nature Genetics, 38, 787-793. <br>https://doi.org/10.1200/JCO.20.02088Le, D., Kim, T.W., Van Cutsem, E., et al. (2020) Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatel-lite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical On-cology, 38, 11-19. <br>https://doi.org/10.1200/JCO.19.02107Jang, M.H., Kim, S., Hwang, D.Y., et al. (2017) BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. Journal of Korean Medical Science, 32, 38-46. <br>https://doi.org/10.3346/jkms.2017.32.1.38Andre, T., Shiu, K.K., Kim, T.W., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England Journal of Medicine, 383, 2207-2218. <br>https://doi.org/10.1056/NEJMoa2017699Schadendorf, D., Hodi, F.S., Robert, C., et al. (2015) Pooled Anal-ysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Mela-noma. Journal of Clinical Oncology, 33, 1889-1894.
<br>https://doi.org/10.1200/JCO.2014.56.2736Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833.
<br>https://doi.org/10.1056/NEJMoa1606774Grassi, E., Corbelli, J., Papiani, G., Barbera, M.A., Gazzaneo, F. and Tamberi, S. (2021) Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Frontiers in On-cology, 11, Article ID: 601722.
<br>https://doi.org/10.3389/fonc.2021.601722Overman, M.J., Lonardi, S., Wong, K., et al. (2018) Durable Clini-cal Benefit with Nivolumab plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Meta-static Colorectal Cancer. Journal of Clinical Oncology, 36, 773-779. <br>https://doi.org/10.1200/JCO.2017.76.9901